Table 5.
Group Side effect |
Group(P) (n = 30) |
Group(E) (n = 30) |
Group(D) (n = 30) |
Group(D/E) (n = 30) |
p |
---|---|---|---|---|---|
PONV (%) IIII&IV |
13 (43.3%)* | 7 (23.3%) | 7 (23.3%) | 5 (16.6%) | 0.027 |
Somnolence | 1 (3.3%) | 1 (3.3%) | 2 (6.7%) | 3 (10%) | 0.225 |
Pruritus | 5 (16.7%) | 4 (13.3%) | 3 (10%) | 3 (10%) | 0.390 |
Dizziness | 1 (3.3%) | 2 (6.7%) | 4 (13.3%) | 3 (10%) | 0.239 |
Headache | 6 (20%) | 3 (10%) | 5 (16.7%) | 4 (13.3%) | 0.907 |
Data are presented as number (%). Data were analyzed using chi square test and fisher’s exact test. Placebo group (P), Etoricoxib (E), Duloxetine (D), Duloxetine/Etoricoxib (D/E). P < 0.05 is considered significant. *P = 0.024 when compare P and D/E